[ad_1]
If a record-breaking IPO wasn’t enough to put RemeGen on the map, perhaps a deal with Seagen – with $ 200 million in cash – could.
At the center of the licensing agreement is disitamab vedotin, an anti-HER2 antibody-drug conjugate that will slip directly into Seagen’s pipeline, except in certain Asian countries where Chinese company RemeGen will retain development and commercialization rights.
ADC’s specialist colleagues have been following each other for some time, Jianmin Fang, CEO of RemeGen told me, as her trans-Pacific team tapped Seagen’s linkage technology and kept them abreast of clinical data. It just so happens to be a good time to pull the trigger.
Keep Reading Endpoints With A Free Membership
Unlock this story instantly and join over 113,700 biopharmacy professionals reading Endpoints daily, and it’s free.
[ad_2]
Source link